IDEAYA Biosciences (IDYA) Expected to Release Earnings on Monday

IDEAYA Biosciences (NASDAQ:IDYA) is projected to announce its Q3 2026 results before the market opens on Monday, November 9th. Analysts expect IDEAYA Biosciences to post earnings of ($1.18) per share and revenue of $7.58 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 12:30 PM ET.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.06) by ($0.16). The company had revenue of $8.86 million during the quarter, compared to analyst estimates of $8.02 million. IDEAYA Biosciences had a negative return on equity of 16.73% and a negative net margin of 75.93%. The business’s revenue for the quarter was up 8800.0% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.88) earnings per share. On average, analysts expect IDEAYA Biosciences to post ($4.52) EPS for the current fiscal year and ($4.42) EPS for the next fiscal year.

IDEAYA Biosciences Stock Performance

Shares of IDYA opened at $31.96 on Monday. The company has a 50-day simple moving average of $37.24 and a 200-day simple moving average of $34.09. The firm has a market capitalization of $2.81 billion, a P/E ratio of -16.47 and a beta of 0.08. IDEAYA Biosciences has a 52 week low of $26.81 and a 52 week high of $42.68.

Insider Buying and Selling at IDEAYA Biosciences

In other news, CEO Yujiro Hata sold 26,338 shares of the company’s stock in a transaction that occurred on Tuesday, October 6th. The shares were sold at an average price of $37.41, for a total transaction of $985,304.58. Following the transaction, the chief executive officer directly owned 690,695 shares in the company, valued at approximately $25,838,899.95. This represents a 3.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 4.70% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have commented on IDYA shares. Truist Financial cut their price target on IDEAYA Biosciences from $63.00 to $59.00 and set a “buy” rating for the company in a report on Wednesday, August 5th. Citigroup reissued a “market outperform” rating on shares of IDEAYA Biosciences in a report on Monday, October 19th. Citizens Jmp reissued a “market outperform” rating and set a $42.00 price objective on shares of IDEAYA Biosciences in a report on Tuesday, September 1st. Mizuho set a $44.00 target price on IDEAYA Biosciences in a research note on Thursday. Finally, Wall Street Zen lowered IDEAYA Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $50.55.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc (NASDAQ:IDYA) is a biotechnology company focused on discovering and developing precision medicines for cancer. Its research emphasizes synthetic lethality, biomarker-driven drug discovery and molecularly defined patient populations, with the goal of matching targeted therapies to specific genetic alterations in tumors.

The company’s pipeline includes darovasertib, an investigational protein kinase C inhibitor being studied primarily for genetically defined cancers, including metastatic uveal melanoma.